164593-05-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(2,6-DIFLUOROPHENYL)-1H-1,3-BENZODIAZOLE is used as a pharmaceutical intermediate for the development of new drugs targeting a range of medical conditions. Its unique structure and properties make it a promising candidate for creating novel therapeutic agents.
Used in Research:
In the field of research, 2-(2,6-DIFLUOROPHENYL)-1H-1,3-BENZODIAZOLE is utilized as a fluorescent probe. It aids scientists in visualizing and studying cellular processes, providing insights into biological mechanisms and pathways.
Used in Organic Synthesis:
2-(2,6-DIFLUOROPHENYL)-1H-1,3-BENZODIAZOLE is employed as a valuable building block in organic synthesis. Its presence in the synthesis of complex organic molecules contributes to the creation of advanced materials and compounds.
Used in Materials Science:
In materials science, 2-(2,6-DIFLUOROPHENYL)-1H-1,3-BENZODIAZOLE is used for its potential applications in developing new materials with specific properties, such as improved stability or reactivity.
Used in Biochemistry:
2-(2,6-DIFLUOROPHENYL)-1H-1,3-BENZODIAZOLE is also applied in biochemistry, where it may be involved in the study of enzyme mechanisms, the development of biosensors, or the creation of bioactive molecules.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 385-00-2 2,6-difluorobenzoic acid 
• 437-81-0 2,6-difluorobenzaldehyde 
• 4403-69-4 2-amino-1-benzylamine 
• 85118-00-9 2,6-Difluorobenzyl bromide 
• 18063-02-0 2,6-difluorobenzoylchloride 
• 88-74-4 2-nitro-aniline 
• 199594-48-4 2,6-difluoro-N-(2-nitrophenyl)benzamide 

Downstream Products

• 199594-59-7 1-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)benzoimidazole 
• 1015084-74-8 [CoCl₂(2-(2,6-difluorophenyl)-1H-benzimidazole)2] 
• 199594-60-0 1-benzyl-2-(2,6-difluorophenyl)benzimidazole 

Relevant academic research and scientific papers

POLYMERIC ANION-CONDUCTING MEMBRANE

The present invention provides compounds, especially polymeric compounds, having at least one imidazole and/or imidazolium structural unit, a process for preparation thereof and for the use thereof.

Accessing Benzimidazoles via a Ring Distortion Strategy: An Oxone Mediated Tandem Reaction of 2-Aminobenzylamines

An exceptional oxone mediated tandem transformation of 2-aminobenzylamines to 2-substituted benzimidazoles is reported. It occurs at room temperature with aromatic, heteroaromatic, and aliphatic aldehydes. In this reaction initial condensation of 2-aminobenzylamine with appropriate aldehydes afforded a tetrahydroquinazoline intermediate which underwent oxone-mediated ring distortion to afford the desired compounds in moderate to excellent yields.

Synthesis of benzimidazoles by copper-catalyzed aerobic oxidative domino reaction of 1,2-diaminoarenes and arylmethyl halides

Arylmethyl halides are readily synthesized via halogenation from the basic raw materials, even in green processes. They are used to replace their downstream products to prepare medicinally important 2-aryl benzimidazoles. CuBr-catalyzed synthesis of 2-aryl benzimidazoles from arylmethyl halides and 1,2-diaminoarenes via a one-pot domino reaction is developed. This new synthetic method is simple, practical and cost saving, and tolerates wide functional groups. A mechanism of CuBr-catalyzed aerobic oxidative domino reaction via a one-pot four-step process is proposed.

Novel non-chelated cobalt(II) benzimidazole complex catalysts: Synthesis, crystal structures and cocatalyst effect in vinyl polymerization of norbornene

The novel non-chelated monodentate benzimidazole (BI) complexes CoCl2(BI)2 (1)-(3), where BI = 1-(2-methoxybenzyl)- 2-(2-methoxyphenyl)-1H-benzimidazole (1), BI = 2-(2,6-difluorophenyl)-1H-benzimidazole (2) and 2-methyl-1H-benzimidaz

Microwave-assisted one step high-throughput synthesis of benzimidazoles

One-pot synthesis of benzimidazoles from diamines and carboxylic acids was developed under microwave irradiation condition, which provided a practical and efficient method for high-throughput synthesis of this important class of heterocyclic compounds.

Novel N-ferrocenylmethyl, N′-methyl-2-substituted benzimidazolium iodide salts with in vitro activity against the P. falciparum malarial parasite strain NF54

Herein we disclose results of our research into a novel class of benzimidazolium compounds active against malarial parasites. We have discovered that N-ferrocenylmethyl, N′-methyl-2-aryl (or styryl) benzimidazolium iodide salts show excellent in vitro activity against the P. falciparum malarial parasite strain NF54.

Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles

The development of new nonnucleoside inhibitors of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT) active against the drug-induced mutations in RT continues to be a very important goal of AIDS research. We used a known inhibitor of HIV-1 RT, 1-(2,6- difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole (TZB), as the lead structure for drug design with the objective of making more potent inhibitors against both wild-type (WT) and variant RTs. A series of structurally related 1,2-substituted benzimidazoles was synthesized and evaluated for their ability to inhibit in vitro polymerization by HIV-1 WT RT. A structure- activity study was carried out for the series of compounds to determine the optimum groups for substitution of the benzimidazole ring at the N1 and C2 positions. The best inhibitor, 1-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)- 4-methylbenzimidazole (35), has an IC50 = 200 nM against HIV-1 WT RT in an in vitro enzyme assay. Cytoprotection assays utilizing HIV-infected MT-4 cells revealed that 35 had strong antiviral activity (EC50 = 440 nM) against wild-type virus while retaining broad activity against many clinically observed HIV-1 strains resistant to nonnucleoside inhibitors. Overall, the activity of 35 against wild-type and resistant strains with amino acid substitution in RT is 4-fold or greater than that of TZB and is comparable to that of other nonnucleoside inhibitors currently undergoing clinical trials, most of which do not have the capacity to inhibit the variant forms of the enzyme.